Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1633069

This article is part of the Research TopicDiagnosis and Management of Pancreatic CancerView all 4 articles

TFF2, a novel serum diagnostic biomarker for early Pancreatic cancer

Provisionally accepted
Xiangyu  WuXiangyu WuXiuhong  HuangXiuhong Huang*
  • Handan Central Hospital, Handan, China

The final, formatted version of the article will be published soon.

Background: Early detection and intervention are critical for improving the prognosis of pancreatic cancer (PC), but effective screening tests remain unavailable. Methods: A retrospective analysis was conducted on 92 PC cases, 50 benign pancreatic disease cases, 92 periampullary adenocarcinoma cases, and 92 healthy controls from September 2020 to September 2024 at Handan Central Hospital. Serum levels of CA199 and CEA were measured, and their diagnostic performance was evaluated by the area under the receiver operating characteristic (ROC) curve (AUC). Additionally, publicly available cancer genome datasets were analyzed to identify specific serum biomarkers for early PC, and clinical serum samples were collected to validate their expression and diagnostic utility. Results: CA199 and CEA effectively differentiated PC from benign pancreatic diseases and normal controls. However, they demonstrated limited value for distinguishing PC and periampullary carcinoma, with AUC values of 0.571 and 0.604, respectively. Trefoil factor 2 (TFF2), a gene encoding exocrine protein, was found to be specifically upregulated in pancreatic intraepithelial neoplasia and PC, with no significant expression observed in benign pancreatic diseases, cholangiocarcinoma, or hepatocellular carcinoma. Importantly, serum TFF2 levels were significantly elevated in the PC group, with AUC values of 0.947 for distinguishing PC from normal controls and 0.856 for differentiating it from periampullary adenocarcinoma, outperforming CA199 and CEA. The combination of TFF2 enhanced accuracy of CA199 and CEA to discriminate PC from periampullary adenocarcinoma. Conclusions: Serum TFF2 is a promising test for early screening of PC and may enhance diagnostic performance when combined with CA199 and CEA.

Keywords: TFF2, CA199, serum biomarker, non-invasive, Pancreatic Cancer

Received: 22 May 2025; Accepted: 02 Sep 2025.

Copyright: © 2025 Wu and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Xiuhong Huang, Handan Central Hospital, Handan, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.